Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Efficacy of different pharmaceutical forms of Curcuma longa or curcumin in reducing oral mucositis severity and incidence in cancer patients: a systematic review and meta-analysis.

  • 2025-04-02
  • Frontiers in pharmacology 16
    • Pedro de Padua G Amatto
    • Lucas Chaves
    • Suzelei de Castro França
    • José Carlos Tavares Carvalho
    • Fabio Carmona
    • Ana Maria Soares Pereira

Study Design

Type
Systematic Review
Sample size
n = 159
Population
cancer patients undergoing chemotherapy and/or radiotherapy for cancer, experiencing oral mucositis
Methods
Systematic review and meta-analysis of randomized clinical trials, searches in PubMed, Embase, and Cochrane databases, comparing Curcuma longa or curcumin with placebo, using fixed- or random-effects models

Background

Curcuma longa L. (turmeric, Zingiberaceae) has been traditionally used for its anti-inflammatory, wound-healing, and antimicrobial properties. These characteristics have made it a key component in managing inflammatory and ulcerative conditions like oral mucositis (OM). This study aimed to evaluate the effectiveness of various pharmaceutical formulations of C. longa or curcumin in reducing the OM severity, incidence and associated pain in patients undergoing chemotherapy and/or radiotherapy for cancer.

Methods

This systematic review and meta-analysis of randomized clinical trials was conducted according to PRISMA guidelines, registered in PROSPERO (#CRD42024504111). Searches were performed in PubMed, Embase, and Cochrane databases. Studies comparing C. longa or curcumin with placebo in cancer patients experiencing oral mucositis, reporting outcomes such as the World Health Organization Oral Mucositis Grading Scale, pain scores (visual analogue scale), or OM incidence were included. Risk ratios and weighted mean differences with 95% confidence intervals were calculated using fixed- or random-effects models.

Results

Six studies with 159 patients (mean age ∼50 years, 40% women) were included. C. longa extracts, curcumin, or nanocurcumin were administered in capsules, mouthwash, or gel formulations. The pooled analysis showed significant reductions in WHO scores and oral pain compared to placebo. OM incidence decreased by 6% overall, with a notable 37%-reduction observed in patients using curcumin-containing mouthwash during radiotherapy alone. Subgroup analyses revealed consistent benefits across all oncological treatments.

Conclusion

C. longa, curcumin, or nanocurcumin in various formulations, effectively reduce OM severity and pain while curcumin-containing mouthwash reduced OM incidence in cancer patients undergoing treatment.

Systematic review registration

identifier CRD 42024504111.

Research Insights

  • Turmeric→Reduced Oral Mucositis Severity

    The pooled analysis showed significant reductions in WHO scores and oral pain compared to placebo.

    Effect
    Beneficial
    Effect size
    Moderate
  • Turmeric→Reduced Oral Pain

    The pooled analysis showed significant reductions in WHO scores and oral pain compared to placebo.

    Effect
    Beneficial
    Effect size
    Moderate
Back to top